The Chicago Tribune Names Takeda Pharmaceuticals U.S.A., Inc. A Workplace Achiever of the Chicago Area 2017 Top Workplaces Award

DEERFIELD, Ill., Nov. 10, 2017

"We are honored to be recognized for our outstanding workplace by the Chicago Tribune for the sixth-consecutive year," said Laurene Giagnorio, Takeda Pharmaceuticals U.S.A.'s senior vice president, head of human resources and administration. "At Takeda, our focus on putting people first extends from our employees and patients to the communities in which we live and work, so this recognition is particularly gratifying given our commitment to the Chicagoland marketplace."

"The Top Workplaces award is not a popularity contest. And oftentimes, people assume it's all about fancy perks and benefits," says Doug Claffey, CEO of Energage. "But to be a Top Workplace, organizations must meet our strict standards for organizational health. And who better to ask about work life than the people who live the culture every day—the employees. Time and time again, our research has proven that what's most important to them is a strong belief in where the organization is headed, how it's going to get there, and the feeling that everyone is in it together. Claffey adds, "Without this sense of connection, an organization doesn't have a shot at being named a Top Workplace."

For Takeda, the recognition from this award builds on positive employee feedback generated in part by the company's ongoing investments in its 70-acre Deerfield campus, which aim to provide a more collaborative and engaging work environment. The multi-million dollar capital improvement project, announced in October 2017, will result in updates that fit employees' professional and personal needs. The facility serves as the footprint for Takeda's U.S. commercial headquarters and also houses various global operations roles for Takeda's marketed products portfolio.

About Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited (TSE: 4502) is a global, R&D-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its research efforts on oncology, gastroenterology and central nervous system therapeutic areas. It also has specific development programs in specialty cardiovascular diseases as well as late-stage candidates for vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. New innovative products, especially in oncology, central nervous system and gastroenterology, as well as its presence in emerging markets, fuel the growth of Takeda. More than 30,000 Takeda employees are committed to improving quality of life for patients, working with our partners in health care in more than 70 countries.